

IN THE CLAIMS:

All of the pending claims 10, 12 through 18, 21, 22, and 31 are presented herein. This listing of claims will replace all prior versions and listings of claims in the application. Please enter these claims as amended.

Listing of Claims:

1-9. (Canceled).

10. (Currently Amended) A method for obtaining an infectious recombinant very virulent Infectious Bursal Disease Virus (vvIBDV), said method comprising:

transfecting at least one first cell, which cell is non-permissive for vvIBDV, with a nucleic acid comprising a vvIBDV genome;

incubating said at least one first cell in a culture medium, so as to produce recombinant vvIBDV which recombinant vvIBDV does not infect said at least one first cell, and which further retains its vvIBDV character;

~~recovering-rescuing said recombinant vvIBDV~~ from said at least one transfected first cell or said culture medium; and

propagating said recovered rescued recombinant vvIBDV in at least one second cell which is permissive for said vvIBDV.

11. (Canceled).

12. (Previously Presented) The method according to claim 10 wherein said at least one first cell is a non-bursa cell-derived cell.

13. (Previously Presented) The method according to claim 12 wherein said at least one second cell is a bursa cell-derived cell.

14. (Previously Presented) The method according to claim 12 wherein said at least one first cell is a CEF cell, a VERO cell or a QM5 cell.

15. (Previously Presented) The method according to claim 14 wherein said at least one first cell has additionally been provided with a helper virus or a viral protein derived from a helper virus.

16. (Previously Presented) The method according to claim 15 wherein said viral protein comprises T7-polymerase.

17. (Previously Presented) The method according to claim 16 wherein said vvIBDV has at least retained the incapacity to be propagated on a vvIBDV non-permissive cell selected from the group consisting of a VERO, a QM5 and a CEF cell.

18. (Previously Presented) The method according to claim 13 wherein said at least one second cell is a primary bursa cell.

19. (Canceled).

20. (Canceled).

21. (Previously Presented) The method according to claim 10 wherein said vvIBDV comprises a serotype II IBDV nucleic acid.

22. (Previously Presented) The method according to claim 21 wherein said vvIBDV is lacking at least one immunodominant epitope specific for a serotype I IBDV.

23-30. (Canceled).

31. (Previously Presented) The method according to claim 10 wherein said at least one second cell is a bursa cell-derived cell.